SIREN : 449653724
NOVETUDE SANTE PRO II is a French company founded 22 years ago, specialized in the sector Formation continue d'adultes. Based in LYON (69007), this company of category ETI shows in 2024 a revenue of 9.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9 012 638 € | 5 937 634 € | 3 439 404 € | 2 306 311 € | 1 788 521 € | 1 421 107 € | 1 031 103 € | 1 077 330 € | 1 108 725 € |
| Net income | -2 082 133 € | 354 771 € | 562 528 € | 243 240 € | 152 538 € | -85 512 € | -123 131 € | 138 565 € | 2 178 677 € |
| EBITDA | 1 848 822 € | 829 221 € | 711 229 € | 527 447 € | 396 173 € | 4 327 € | -57 189 € | -14 806 € | 191 842 € |
| Net margin | -23.1% | 6.0% | 16.4% | 10.5% | 8.5% | -6.0% | -11.9% | 12.9% | 196.5% |
In 2024, NOVETUDE SANTE PRO II achieves revenue of 9.0 M€. Over the period 2016-2024, the company shows strong growth with a CAGR (compound annual growth rate) of +29.9%. Vs 2023, growth of +52% (5.9 M€ -> 9.0 M€). After deducting consumption (-11 k€), gross margin stands at 9.0 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.8 M€, representing 20.5% of revenue. Positive scissor effect: EBITDA margin improves by +6.5 pts, sign of improved operational efficiency. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Net income is negative at -2.1 M€ (-23.1% of revenue), which will impact equity.
9 012 638 €
9 023 214 €
1 848 822 €
-1 623 712 €
-2 082 133 €
20.2%
The debt ratio (= Financial debt / Equity x 100) stands at 39%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.5 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 15.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
39.359%
5.796%
15.162%
0.472
71.1%
In 2024, the debt ratio of NOVETUDE SANTE PRO II (39.36) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of NOVETUDE SANTE PRO II (5.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of NOVETUDE SANTE PRO II (0.47) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 39.05. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 15.5x. Operating income very largely covers interest expenses: high safety margin.
39.046
15.485
In 2024, the liquidity ratio of NOVETUDE SANTE PRO II (39.05) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of NOVETUDE SANTE PRO II (15.5x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 148 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 196 days. Excellent situation: suppliers finance 48 days of the operating cycle (retail model). WCR is negative (-657 days): operations structurally generate cash. Notable WCR improvement over the period (-17543%), freeing up cash.
-16 448 245 €
148 j
196 j
0 j
-657 j
Based on 134 transactions of similar company sales (all years), the value of NOVETUDE SANTE PRO II is estimated at 3 713 398 € (range 1 310 907€ - 8 878 021€). With an EBITDA of 1 848 822€, the sector multiple of 2.2x is applied. The price/revenue ratio is 0.36x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 134 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare NOVETUDE SANTE PRO II with other companies in the same sector:
Voir toutes les statistiques du secteur Formation continue d'adultes
The revenue of NOVETUDE SANTE PRO II in 2024 is 9.0 M€.
NOVETUDE SANTE PRO II recorded a net loss in 2024.
The headquarters of NOVETUDE SANTE PRO II is located in LYON (69007), in the department Rhone.
The tax return of NOVETUDE SANTE PRO II is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
NOVETUDE SANTE PRO II operates in the sector Formation continue d'adultes (NAF code 85.59A). See the 'Sector positioning' section above to compare the company with its competitors.